3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Polycystic Ovary Syndrome
7
Breast Neoplasms
4
Peripheral Nervous System Diseases
2
Squamous Cell Carcinoma of Head and Neck
1
Radiodermatitis
1
Primary Ovarian Insufficiency
1
Ototoxicity
1
Neurotoxicity Syndromes
1
Nervous System Diseases
1
Mucositis
1
Insulin Resistance
1
Infertility, Female
1
Infertility
1
Hyperandrogenism
1
Head and Neck Neoplasms
1
Disease Progression
1
Cisplatin Nephrotoxicity
1
Carcinoma, Non-Small-Cell Lung
1
Breast Cancer Female
1
Interventions
Lenalidomide
4
Gemcitabine
4
Dexamethasone
4
Cyclophosphamide
4
Bortezomib
4
Nivolumab
3
Cisplatin
3
Carboplatin
3
vandetanib
2
tumor necrosis factor-alpha, CNGRC fusion protein, human
2
pomalidomide
2
pembrolizumab
2
liposomal doxorubicin
2
fludarabine
2
durvalumab
2
capivasertib
2
Paclitaxel
2
Doxorubicin
2
Bevacizumab
2
venetoclax
1
umbralisib
1
ublituximab
1
tremelimumab
1
tivozanib
1
ricolinostat
1
regorafenib
1
pazopanib
1
niraparib
1
nilotinib
1
neratinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Disease Progression
×
Thioctic Acid
×
Clear all
NCT07574684
2026-05-08
ALA /NSCLC
Ain Shams University
Phase 2
Not yet recruiting
60 enrolled